CME's third-quarter profit falls as weak energy trading hits fees-February 2024-www.financetom.com

CME's third-quarter profit falls as weak energy trading hits fees

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

CME's third-quarter profit falls as weak energy trading hits fees

Oct 22, 2025 4:25 AM

Oct 22 (Reuters) - Derivatives exchange CME Group ( CME )

reported a fall in third-quarter profit on Wednesday, as

subdued energy volumes weighed on transaction fees.

Profit attributable to CME shareholders was $896.6 million,

or $2.49 per share, for the three months ended September 30.

That compares with $901.3 million, or $2.50 per share, a year

earlier.

Previous page： Arizona Sonoran Reports Latest Drilling Assays Around Cactus West Pit Next page： Merck Says Keytruda With Chemoradiotherapy Lowers Risk of Death in Cervical Cancer Trial

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Arizona Sonoran Reports Latest Drilling Assays Around Cactus West Pit

Sep 16, 2024

07:27 AM EDT, 09/16/2024 (MT Newswires) -- Arizona Sonoran Copper ( ASCUF ) reported Monday drill assay results from its infill and step-out drilling program around the Cactus west pit within the Cactus project in Arizona. Highlights include 646 meters at 0.40% total copper, 643 meters at 0.31% total copper and 579 meters at 0.33% total copper. The results were...

Merck Says Keytruda With Chemoradiotherapy Lowers Risk of Death in Cervical Cancer Trial

Sep 16, 2024

07:28 AM EDT, 09/16/2024 (MT Newswires) -- Merck ( MRK ) said Saturday that results from a phase 3 trial showed that Keytruda with chemoradiotherapy reduced the risk of death in patients newly diagnosed with high-risk locally advanced cervical cancer compared with chemoradiotherapy alone. Merck ( MRK ) said Keytruda combined with chemoradiotherapy decreased the risk of death by 33%...

Merck Says 10-Year Keytruda Phase 3 Trial Results Show Sustained Survival

Sep 16, 2024

07:28 AM EDT, 09/16/2024 (MT Newswires) -- Merck ( MRK ) said Sunday that long-term results from a phase 3 trial of Keytruda as treatment for advanced melanoma showed sustained improved survival outcomes. The 10-year overall survival rate for Keytruda was 34%, higher than 23.6% for alternative drug ipilimumab, Merck ( MRK ) said. The median OS for Keytruda-treated patients...

Bristol-Myers Squibb Reports Opdivo, Yervoy Combination's Continued Survival Benefit in Advanced Melanoma

Sep 16, 2024

07:24 AM EDT, 09/16/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Sunday that 10-year follow-up data from a phase 3 trial of Opdivo monotherapy and Opdivo in combination with Yervoy in advanced or metastatic melanoma showed continued long-term survival benefit. The trial enrolled 945 patients with previously untreated advanced melanoma and after a minimum follow-up of 10 years,...